Creative Biolabs has announced the expansion of its advanced single-cell multi-omics and RNA sequencing solutions, a move that carries significant implications for biomedical research. The upgraded suite of services is designed to meet the escalating demand for high-resolution cellular profiling, offering end-to-end workflows that range from single-cell transcriptome profiling to integrated multimodal and multi-omics analyses. This development matters because it directly addresses a critical bottleneck in modern life science research: the need to understand cellular heterogeneity at unprecedented resolution.
As research increasingly transitions from bulk tissue profiling to single-cell resolution, dissecting cellular heterogeneity has become essential for identifying rare cell subpopulations, characterizing complex tumor microenvironments, and tracing cell lineage trajectories. Creative Biolabs now delivers robust, high-throughput single-cell RNA sequencing services that offer high sensitivity and coverage across thousands of individual cells, providing high-resolution transcriptomic insights from diverse fresh biological specimens. This capability is crucial for researchers seeking to uncover the molecular underpinnings of disease and develop targeted therapies.
A key implication of this expansion is the platform's specialized single-nucleus RNA sequencing (snRNA-seq) capabilities. For tissues where single-cell dissociation is prone to cell damage, dissociation-induced stress responses, or selective loss of fragile cell types—such as human brain, myocardium, or flash-frozen clinical biopsies—Creative Biolabs provides an optimized single-cell nuclei RNA sequencing service. By isolating intact nuclei, this approach bypasses harsh enzymatic dissociation while minimizing dissociation-related artifacts while retaining informative nuclear RNA profiles, dramatically expanding the scope of clinical translational research. This is particularly important for neuroscience and oncology, where access to fresh tissue is limited and archived samples are common.
Recognizing that cellular identity is orchestrated across multiple regulatory layers, Creative Biolabs goes beyond single-dimensional analysis by advancing its high-throughput single-cell multi-omics service. This integrated platform allows the simultaneous interrogation of genomic variations, epigenomic landscapes (e.g., chromatin accessibility), cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, the service enables researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented biological clarity. This integration is a game-changer for precision medicine, as it provides a more holistic view of cellular states and disease mechanisms.
"Understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery," said a senior scientist at Creative Biolabs. "Our goal is to provide researchers with a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support." This statement underscores the broader impact of the announcement: by offering a comprehensive suite of services supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs is empowering academic and biopharmaceutical research teams worldwide to unravel the complexities of human disease. The expansion not only enhances research capabilities but also accelerates the translation of single-cell discoveries into clinical applications, ultimately benefiting patients through more precise diagnostics and therapies.
